Image

In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.

Description

Patients with in-hospital cardiac arrest (IHCA) outside the operating room, the coronary angiography suite and the intensive care unit (ICU) will be attended to by the hospitals resuscitation team and provided with advanced cardiac life support (ACLS) as per usual practice.

A research team will be deployed simultaneously and, when patients meet inclusion criteria, will randomize patients to ACLS alone or to ACLS plus balloon occlusion of the descending thoracic aorta by means of a resuscitative endovascular occlusion of the aorta (REBOA) catheter.

Eligibility

Inclusion criteria:

  • patients suffering from in hospital cardiac arrest (IHCA), including patients with out of hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC), transported to the emergency department, where they suffer a second arrest (IHCA)
  • successful placement of a femoral artery introducer sheath
  • any electrical cardiac activity seen in the initial rhythm analysis
  • ongoing effort of resuscitation as determined by study-independent resuscitation lead

Exclusion criteria:

  • IHCA in the operating room, on intensive care unit or in the cardiac catheter laboratory
  • hospital visitors suffering from cardiac arrest
  • asystole seen in the initial rhythm analysis
  • (presumed) age under 18 years
  • known "do not resuscitate"-order
  • known or obvious pregnancy
  • traumatic cardiac arrest
  • known aortic pathologies that render cannulation impossible
  • known allergies to radiographic contrast agents

Study details
    Cardiac Arrest

NCT07434726

Insel Gruppe AG, University Hospital Bern

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.